Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance for a Further Two Years

20-Dec-2011 - United Kingdom

Sygnature Discovery Ltd. and Cyprotex Discovery Ltd announced they have entered into an extension of their highly successful strategic alliance for a further 2 years.  Under the terms of the extension of the agreement, Sygnature and Cyprotex will expand their collaborative sales and marketing initiative to provide a fully-integrated discovery chemistry/ADME-Tox/DMPK service to accelerate their clients’ drug discovery projects into development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances